Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial

药代动力学 银屑病 医学 双盲 安慰剂 生物标志物 随机对照试验 肿瘤科 内科学 药理学 皮肤病科 病理 替代医学 化学 生物化学
作者
James G. Krueger,Laura Korb Ferris,Alan Menter,Frank Dietrich Wagner,Alexander White,Sudha Visvanathan,Bojan B. Lalovic,Stella Aslanyan,Elaine E. L. Wang,David Hall,Alan M. Solinger,Steven J. Padula,Paul R. Scholl
出处
期刊:The Journal of Allergy and Clinical Immunology [Elsevier BV]
卷期号:136 (1): 116-124.e7 被引量:273
标识
DOI:10.1016/j.jaci.2015.01.018
摘要

BackgroundIL-23 is associated with plaque psoriasis susceptibility and pathogenesis. BI 655066 is a fully human IgG1 mAb specific for the IL-23 p19 subunit.ObjectiveThis first-in-human proof-of-concept study evaluated the clinical and biological effects of BI 655066 in patients with moderate-to-severe plaque psoriasis.MethodsWe performed a single-rising-dose, multicenter, randomized, double-blind, placebo-controlled, within-dose cohort phase I trial. Patients received 0.01, 0.05, 0.25, 1, 3, or 5 mg/kg BI 655066 intravenously, 0.25 or 1 mg/kg BI 655066 subcutaneously, or matched placebo. The primary objective was safety evaluation.ResultsThirty-nine patients received single-dose BI 655066 intravenously (n = 18) or subcutaneously (n = 13) or placebo (n = 8). Adverse events were reported with similar frequency in the BI 655066 and placebo groups. Four serious adverse events (not considered treatment related) were reported among BI 655066–treated patients. BI 655066 was associated with clinical improvement from week 2 and maintained for up to 66 weeks after treatment. At week 12, 75%, 90%, and 100% decreases in the Psoriasis Area and Severity Index were achieved by 87%, 58%, and 16% of BI 655066–treated patients (any dose), respectively, versus none receiving placebo. BI 655066 treatment resulted in reduced expression of lesional skin genes associated with IL-23/IL-17 signaling pathways and normalization of psoriatic lesion gene expression profiles to a profile approaching that of nonlesional skin. Significant correlation between treatment-associated molecular changes and psoriasis area and severity index improvement was observed (r = 0.73, P = 2 × 10−6).ConclusionsBI 655066 was well tolerated and associated with rapid, substantial, and durable clinical improvement in patients with moderate-to-severe psoriasis, supporting a central role for IL-23 in psoriasis pathogenesis. IL-23 is associated with plaque psoriasis susceptibility and pathogenesis. BI 655066 is a fully human IgG1 mAb specific for the IL-23 p19 subunit. This first-in-human proof-of-concept study evaluated the clinical and biological effects of BI 655066 in patients with moderate-to-severe plaque psoriasis. We performed a single-rising-dose, multicenter, randomized, double-blind, placebo-controlled, within-dose cohort phase I trial. Patients received 0.01, 0.05, 0.25, 1, 3, or 5 mg/kg BI 655066 intravenously, 0.25 or 1 mg/kg BI 655066 subcutaneously, or matched placebo. The primary objective was safety evaluation. Thirty-nine patients received single-dose BI 655066 intravenously (n = 18) or subcutaneously (n = 13) or placebo (n = 8). Adverse events were reported with similar frequency in the BI 655066 and placebo groups. Four serious adverse events (not considered treatment related) were reported among BI 655066–treated patients. BI 655066 was associated with clinical improvement from week 2 and maintained for up to 66 weeks after treatment. At week 12, 75%, 90%, and 100% decreases in the Psoriasis Area and Severity Index were achieved by 87%, 58%, and 16% of BI 655066–treated patients (any dose), respectively, versus none receiving placebo. BI 655066 treatment resulted in reduced expression of lesional skin genes associated with IL-23/IL-17 signaling pathways and normalization of psoriatic lesion gene expression profiles to a profile approaching that of nonlesional skin. Significant correlation between treatment-associated molecular changes and psoriasis area and severity index improvement was observed (r = 0.73, P = 2 × 10−6). BI 655066 was well tolerated and associated with rapid, substantial, and durable clinical improvement in patients with moderate-to-severe psoriasis, supporting a central role for IL-23 in psoriasis pathogenesis.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wnw完成签到,获得积分10
刚刚
刚刚
圆圆完成签到,获得积分10
刚刚
1秒前
1秒前
MM完成签到 ,获得积分10
1秒前
1秒前
小铁的应助被白耀庭采纳,获得10
1秒前
高大的凝阳完成签到,获得积分10
1秒前
今后的应助被www采纳,获得10
1秒前
2秒前
Peiqi的应助被怡然的扬采纳,获得20
2秒前
2秒前
Mayday完成签到,获得积分10
3秒前
洁净的冬日完成签到,获得积分10
3秒前
4秒前
ZsJJkk发布了新的文献求助30
4秒前
周末完成签到 ,获得积分10
4秒前
4秒前
dus116完成签到,获得积分10
4秒前
现安完成签到 ,获得积分10
4秒前
小太阳完成签到,获得积分10
4秒前
Charlie发布了新的文献求助10
5秒前
Fatherrr完成签到,获得积分10
5秒前
5秒前
allezallez完成签到,获得积分10
5秒前
smyster完成签到 ,获得积分10
5秒前
向日葵发布了新的文献求助10
6秒前
6秒前
半夏完成签到,获得积分10
6秒前
贺贺发布了新的文献求助10
7秒前
NexusExplorer的应助被cc采纳,获得10
7秒前
7秒前
7秒前
脑洞疼的应助被材料牛马采纳,获得10
7秒前
Claire完成签到,获得积分10
8秒前
LL完成签到,获得积分10
8秒前
8秒前
阿飞发布了新的文献求助10
8秒前
唐新发布了新的文献求助10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180531
求助须知:如何正确求助?哪些是违规求助? 9570507
关于积分的说明 21812974
捐赠科研通 7776619
什么是DOI,文献DOI怎么找? 3433286
关于科研通互助平台的介绍 2557539
邀请新用户注册赠送积分活动 2479185